These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 35529845

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Serum hepatitis B virus large and medium surface proteins as novel tools for predicting HBsAg clearance.
    Lin X, Zheng Y, Li H, Lu J, Ren S, Liu Y, Wang X, Zheng S, Ma L, Cao Z, Chen X.
    Front Immunol; 2022; 13():1028921. PubMed ID: 36211341
    [Abstract] [Full Text] [Related]

  • 3. Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study.
    Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, Zhou Z, Shi X.
    Front Cell Infect Microbiol; 2023; 13():1332232. PubMed ID: 38292859
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of the therapeutic efficacy and factors influencing sequential combination of nucleos(t)ide analogues with pegylated interferon alpha for 48~96 weeks in the treatment of patients with chronic hepatitis B].
    Jia R, Wang WX, Zhou ZP, Nie WM, Cheng YQ, Zhao J, Lian F, Luan JQ, Wang FS, Fu JL.
    Zhonghua Gan Zang Bing Za Zhi; 2023 Dec 20; 31(12):1290-1296. PubMed ID: 38253073
    [Abstract] [Full Text] [Related]

  • 5. Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis.
    Song A, Lin X, Lu J, Ren S, Cao Z, Zheng S, Hu Z, Li H, Shen C, Chen X.
    Front Immunol; 2021 Dec 20; 12():779347. PubMed ID: 34804072
    [Abstract] [Full Text] [Related]

  • 6. Triple motif proteins 19 and 38 correlated with treatment responses and HBsAg clearance in HBeAg-negative chronic hepatitis B patients during peg-IFN-α therapy.
    Luo H, Tan G, Hu X, Li Y, Lei D, Zeng Y, Qin B.
    Virol J; 2023 Jul 20; 20(1):161. PubMed ID: 37475028
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    Innate Immun; 2020 Oct 20; 26(7):601-608. PubMed ID: 32772775
    [Abstract] [Full Text] [Related]

  • 9. Effect of Pegylated Interferon Plus Tenofovir Combination on Higher Hepatitis B Surface Antigen Loss in Treatment-naive Patients With Hepatitis B e Antigen -positive Chronic Hepatitis B: A Real-world Experience.
    Hu C, Song Y, Tang C, Li M, Liu J, Liu J, Liao M, Zhou F, Zhang YY, Zhou Y.
    Clin Ther; 2021 Mar 20; 43(3):572-581.e3. PubMed ID: 33516527
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].
    Yu HB, Ma LN, Liu YL, Hua W, He ZM, Lu JF, Chen XY.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Dec 20; 21(12):895-8. PubMed ID: 24636289
    [Abstract] [Full Text] [Related]

  • 12. [Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
    Jia R, Wang WX, Gao YY, Luan JQ, Qiao F, Liu JY, Yuan JH, Cheng YQ, Wang FS, Fu JL.
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul 20; 29(7):666-672. PubMed ID: 34371537
    [Abstract] [Full Text] [Related]

  • 13. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study.
    Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS.
    World J Gastroenterol; 2020 Apr 07; 26(13):1525-1539. PubMed ID: 32308352
    [Abstract] [Full Text] [Related]

  • 14. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z, Li X, Shi C, Zhang M, Chen R, Wu W, Hou Q, Ke W, Fan T, Wen Z, Hao X, Qu N.
    Mol Med Rep; 2015 Jan 07; 11(1):427-33. PubMed ID: 25324041
    [Abstract] [Full Text] [Related]

  • 15. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
    Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.
    Hepatology; 2009 Apr 07; 49(4):1151-7. PubMed ID: 19115222
    [Abstract] [Full Text] [Related]

  • 16. Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real-world analysis.
    Zhang W, Xing M, Sun W, Chen J, Xie N, Cai Y, Wang Y, Li N, Jiang Y, Zhang F, Wang Y, Zeng Q, Ji Y, Xu C, Jiang C, Song J, Li G.
    J Viral Hepat; 2023 May 07; 30(5):427-436. PubMed ID: 36562258
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
    Li MH, Hu LP, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Wu YZ, Yang M, Song SJ, Zhang SF, Hua WH, Xie Y, Cheng J, Xu DZ.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Nov 07; 23(11):826-31. PubMed ID: 26743242
    [Abstract] [Full Text] [Related]

  • 18. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.
    Antimicrob Agents Chemother; 2015 Jul 07; 59(7):4121-8. PubMed ID: 25941216
    [Abstract] [Full Text] [Related]

  • 19. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.
    Chen GY, Zhu MF, Zheng DL, Bao YT, Wang J, Zhou X, Lou GQ.
    World J Gastroenterol; 2014 Jul 07; 20(25):8195-200. PubMed ID: 25009392
    [Abstract] [Full Text] [Related]

  • 20. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.
    Antivir Ther; 2012 Jul 07; 17(1):9-17. PubMed ID: 22267464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.